Enhanced therapeutic efficacy of poly(ICLC) and ribavirin combinations against Rift Valley fever virus infection in mice

Antimicrobial Agents and Chemotherapy
M KendeP G Canonico

Abstract

The therapeutic efficacy of polyriboinosinic-polyribocytidylic acid stabilized with poly-L-lysine and carboxymethyl cellulose [poly(ICLC)] given alone or in combination with ribavirin was evaluated in Swiss Webster mice infected with Rift Valley fever virus. Four or more 20-micrograms doses of poly(ICLC) given at various intervals beginning 24 h after infection protected all mice against death. On the other hand, a treatment regimen consisting of only three doses of poly(ICLC) given 24 h postinfection resulted in a 50% survival rate. When initiated 48 h postinfection, an extended treatment regimen with the same dose was required to yield 40% survivors. Lower doses (5 micrograms) of poly(ICLC) per mouse were only marginally effective even when six injections were given between days 1 and 9 postinfection. The combined administration of ribavirin and poly(ICLC) initiated as late as 48 h postinfection was effective even when treatment consisted of doses that were ineffective when either drug was used alone.

References

Jan 1, 1979·Transactions of the Royal Society of Tropical Medicine and Hygiene·J M Meegan
Mar 1, 1983·European Journal of Pediatrics·S Levin
Aug 1, 1984·The Journal of Antimicrobial Chemotherapy·P G CanonicoJ W Huggins
Jan 1, 1980·Annual Review of Pharmacology and Toxicology·R A SmithR K Robins

Citations

Sep 1, 1993·Antiviral Research·G Andrei, E De Clercq
Jul 20, 1999·International Journal of Immunopharmacology·R L MillerM A Tomai
Aug 29, 2012·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Camila C DiasMarvin J Grubman
Mar 28, 2009·International Journal of Molecular Sciences·Mary E Christopher, Jonathan Wong
Jun 16, 1992·Annals of the New York Academy of Sciences·G H TignorC A Hanham
Jun 16, 1992·Annals of the New York Academy of Sciences·M Kende
Jun 16, 1992·Annals of the New York Academy of Sciences·Robert W SidwellM Kende

Related Concepts

Poly ICLC, sodium salt
Metazoa
Ruspol
Drug Administration Schedule
Polychemotherapy
Females
Interferon Inducers
Cologel
Poly I-C
Poly-(Alpha-L-Lysine)

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.